Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

ESMO Targeted Anticancer Therapies Asia Congress 2025

Start date: 18 Jul 2025
End date: 20 Jul 2025
Location: Hong Kong SAR, China

Abstract Deadline: 29 April 2025, 18:00 Hong Kong Time / 12:00 CEST

Early Registration until: 14 May 2025

ESMO TAT Asia 2025: bringing together key stakeholders in early drug development in the Asia-Pacific region

Through collaboration, innovation, and shared expertise, the ESMO TAT Asia Congress aims to bridge the gap between clinicians, academia, regulators and the industry to advance early drug development in oncology and ultimately lead to better cancer care in the region.
Located in Hong Kong SAR, China, a hub for innovative anti-cancer drug development, this meeting will focus on building capacity and accelerating the development of early phase clinical trials, creating strong foundations for oncology drug development.

Join us in Hong Kong SAR, China from 18-20 July for the inaugural TAT Asia Congress.